BioDelivery Sciences International Inc. (BDSI) and Endo International plc (ENDP) have received FDA approval for BELBUCA buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.